Leases (Details Narrative) - Veraxa Biotech A G [Member] - CHF (SFr)	12 Months Ended
Dec. 31, 2025	Dec. 31, 2024
Entity Information [Line Items]
Cash outflow for leases	SFr 188,745
Payment of principal portion of lease liabilities	164,640
Interest paid on lease liabilities.	24,105
Right-of-use assets and lease liabilities	SFr 440,802

The cash outflow for leases.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 16
-IssueDate 2025-01-01
-Paragraph 53
-Subparagraph g
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_g&doctype=Standard
-URIDate 2025-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 115
-Subparagraph f
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_f&doctype=Standard
-URIDate 2025-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 115
-Subparagraph f
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_f&doctype=Standard
-URIDate 2025-03-27

Name:	ifrs-full_CashOutflowForLeases
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration